

Gordon B Mills

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2463874/publications.pdf>

Version: 2024-02-01

834
papers

167,677
citations

⁶⁷

181
h-index

⁸⁰

373
g-index

873
all docs

873
docs citations

873
times ranked

156694
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanical Stress Signaling in Pancreatic Cancer Cells Triggers p38 MAPK- and JNK-Dependent Cytoskeleton Remodeling and Promotes Cell Migration via Rac1/cdc42/Myosin II. <i>Molecular Cancer Research</i> , 2022, 20, 485-497.	1.5	33
2	WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	22
3	Whole-chromosome arm acquired uniparental disomy in cancer development is a consequence of isochromosome formation. <i>Neoplasia</i> , 2022, 25, 9-17.	2.3	5
4	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100525.	3.3	22
5	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 323-339.	12.8	107
6	MITI minimum information guidelines for highly multiplexed tissue images. <i>Nature Methods</i> , 2022, 19, 262-267.	9.0	37
7	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100974.	0.3	5
8	A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis. <i>Communications Biology</i> , 2022, 5, 255.	2.0	20
9	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. <i>Clinical Cancer Research</i> , 2022, , .	3.2	3
10	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. <i>Expert Review of Proteomics</i> , 2022, 19, 115-129.	1.3	3
11	A functional genomic approach to actionable gene fusions for precision oncology. <i>Science Advances</i> , 2022, 8, eabm2382.	4.7	9
12	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 2180-2195.	3.2	12
13	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	2.3	3
14	PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2022, , .	3.3	7
15	Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003340.	1.2	3
16	Ovarian cancer recurrence: is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments? <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 451-458.	0.9	6
17	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
18	A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. <i>Nature Biotechnology</i> , 2022, 40, 1823-1833.	9.4	17

#	ARTICLE	IF	CITATIONS
19	Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. Annual Review of Cancer Biology, 2021, 5, 39-57.	2.3	9
20	Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. Advanced Science, 2021, 8, 2003049.	5.6	15
21	Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. JCO Precision Oncology, 2021, 5, 286-306.	1.5	5
22	Reward Enhances Online Participants'™ Engagement With a Demanding Auditory Task. Trends in Hearing, 2021, 25, 233121652110259.	0.7	9
23	MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Research, 2021, 81, 2714-2729.	0.4	23
24	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. British Journal of Cancer, 2021, 124, 1556-1565.	2.9	9
25	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 2021, 12, 1998.	5.8	37
26	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. Npj Precision Oncology, 2021, 5, 28.	2.3	19
27	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. Journal of the National Cancer Institute, 2021, 113, 1396-1404.	3.0	56
28	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	13.5	135
29	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3243-3252.	3.2	14
30	Spatially interacting phosphorylation sites and mutations in cancer. Nature Communications, 2021, 12, 2313.	5.8	12
31	Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer Letters, 2021, 502, 180-188.	3.2	35
32	mi-IsoNet: systems-scale microRNA landscape reveals rampant isoform-mediated gain of target interaction diversity and signaling specificity. Briefings in Bioinformatics, 2021, 22, .	3.2	9
33	Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer, 2021, 127, 2279-2293.	2.0	9
34	Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 4587-4598.	3.2	14
35	In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. Advanced Materials, 2021, 33, e2100628.	11.1	34
36	Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers. Cell Reports Medicine, 2021, 2, 100349.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. <i>Scientific Reports</i> , 2021, 11, 13630.	1.6	31
38	Ultrastructure of immunogenic cell death in vivo. <i>Microscopy and Microanalysis</i> , 2021, 27, 1390-1391.	0.2	1
39	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. <i>Oncogene</i> , 2021, 40, 5590-5599.	2.6	33
40	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.4	9
41	Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co-delivering CpG and STAT3 siRNA to Effectively Induce Whole-body Antitumor Immune Response (<i>Adv. Mater.</i> 31/2021). <i>Advanced Materials</i> , 2021, 33, 2170244.	11.1	0
42	A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 6800-6814.	3.2	10
43	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	10
44	CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. <i>Cell Reports Medicine</i> , 2021, 2, 100394.	3.3	29
45	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capiwasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6354-6365.	3.2	31
46	TOP1 modulation during melanoma progression and in adaptive resistance to BRAF and MEK inhibitors. <i>Pharmacological Research</i> , 2021, 173, 105911.	3.1	5
47	BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. <i>Theranostics</i> , 2021, 11, 9180-9197.	4.6	4
48	Hormonal modulation of ESR1 mutant metastasis. <i>Oncogene</i> , 2021, 40, 997-1011.	2.6	22
49	Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e608.	1.7	8
50	Multomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. <i>Npj Precision Oncology</i> , 2021, 5, 92.	2.3	11
51	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
52	Profiling of immune features to predict immunotherapy efficacy. <i>Innovation(China)</i> , 2021, 3, 100194.	5.2	13
53	Costimulation of $\hat{1}^3\hat{1}$ TCR and TLR7/8 promotes \hat{V}^2 T-cell antitumor activity by modulating mTOR pathway and APC function. , 2021, 9, e003339.		14
54	Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. <i>International Journal of Cancer</i> , 2020, 147, 413-422.	2.3	31

#	ARTICLE	IF	CITATIONS
55	MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. <i>Oncogene</i> , 2020, 39, 1681-1695.	2.6	50
56	Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1. <i>Npj Breast Cancer</i> , 2020, 6, 2.	2.3	17
57	Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. <i>British Journal of Cancer</i> , 2020, 122, 405-412.	2.9	53
58	Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. <i>Science Advances</i> , 2020, 6, .	4.7	58
59	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. <i>PLoS ONE</i> , 2020, 15, e0239966.	1.1	4
60	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. <i>Cancer Research</i> , 2020, 80, 5554-5568.	0.4	29
61	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	5.8	120
62	Candidate biomarker assessment for pharmacological response. <i>Translational Oncology</i> , 2020, 13, 100830.	1.7	3
63	Transient commensal clonal interactions can drive tumor metastasis. <i>Nature Communications</i> , 2020, 11, 5799.	5.8	30
64	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. <i>Nature Genetics</i> , 2020, 52, 800-810.	9.4	40
65	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. <i>Nature Communications</i> , 2020, 11, 3726.	5.8	169
66	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	3.0	32
67	Integrated Genomic Characterization of the Human Immunome in Cancer. <i>Cancer Research</i> , 2020, 80, 4854-4867.	0.4	11
68	The roles of <i>MAGEA6</i> variants in pancreatic cancer development and their potential impact on cancer immunotherapy. <i>Autophagy</i> , 2020, 16, 1923-1924.	4.3	2
69	Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. <i>Science Advances</i> , 2020, 6, .	4.7	85
70	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	3.2	24
71	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , 2020, 38, 829-843.e4.	7.7	40
72	Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients. <i>Expert Review of Proteomics</i> , 2020, 17, 187-190.	1.3	2

#	ARTICLE	IF	CITATIONS
73	p85 ^{Î²} regulates autophagic degradation of AXL to activate oncogenic signaling. Nature Communications, 2020, 11, 2291.	5.8	23
74	Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nature Biotechnology, 2020, 38, 586-599.	9.4	509
75	Prospecting whole cancer genomes. Nature Cancer, 2020, 1, 273-275.	5.7	0
76	Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosinâ€“Stained Sections of Core-Needle Biopsy Specimens. JAMA Network Open, 2020, 3, e200476.	2.8	19
77	Fibroblastâ€“tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16500-16508.	3.3	23
78	RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics, 2020, 10, 7974-7992.	4.6	42
79	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell, 2020, 37, 371-386.e12.	7.7	68
80	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT Tj ETQq0 0 0 rg8B/Overlook 10 Tf 50	8.5	10
81	Comprehensive assessment of computational algorithms in predicting cancer driver mutations. Genome Biology, 2020, 21, 43.	3.8	47
82	Immuno-genomic landscape of osteosarcoma. Nature Communications, 2020, 11, 1008.	5.8	143
83	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer, 2020, 122, 1014-1022.	2.9	9
84	PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature, 2020, 578, 166-171.	13.7	131
85	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	13.7	1,966
86	Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-Î²B1 Target SerpinE1 in Aggressive Glioblastoma Tumors. Cancers, 2020, 12, 1081.	1.7	22
87	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Molecular Oncology, 2020, 14, 1760-1778.	2.1	27
88	Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays. JCO Clinical Cancer Informatics, 2020, 4, 357-366.	1.0	11
89	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
90	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 2020, 31, 107502.	2.9	69

#	ARTICLE	IF	CITATIONS
91	Acquired Uniparental Disomy Regions Are Associated with Disease Outcome in Patients with Oral Cavity and Oropharynx But Not Larynx Cancers. <i>Translational Oncology</i> , 2020, 13, 100763.	1.7	3
92	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3720-3731.	3.2	21
93	Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. <i>Cancer Immunology Research</i> , 2020, 8, 952-965.	1.6	63
94	Sex-associated molecular differences for cancer immunotherapy. <i>Nature Communications</i> , 2020, 11, 1779.	5.8	144
95	Systems approach to rational combination therapy: PARP inhibitors. <i>Biochemical Society Transactions</i> , 2020, 48, 1101-1108.	1.6	28
96	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 5951-5966.	3.9	72
97	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. <i>Life Science Alliance</i> , 2020, 3, e201900545.	1.3	27
98	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 428-433.	2.3	9
99	Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. <i>ELife</i> , 2020, 9, .	2.8	16
100	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 3947-3972.	1.4	3
101	Title is missing!. , 2020, 15, e0239966.		0
102	Title is missing!. , 2020, 15, e0239966.		0
103	Title is missing!. , 2020, 15, e0239966.		0
104	Title is missing!. , 2020, 15, e0239966.		0
105	Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 251-261.	1.1	15
106	Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. <i>Cell Reports</i> , 2019, 28, 1971-1980.e8.	2.9	42
107	COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 5650-5662.	3.2	83
108	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. <i>Cell Systems</i> , 2019, 9, 35-48.e5.	2.9	95

#	ARTICLE	IF	CITATIONS
109	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	2.2	141
110	The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. <i>Npj Breast Cancer</i> , 2019, 5, 22.	2.3	19
111	Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. <i>Nature Communications</i> , 2019, 10, 4562.	5.8	165
112	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2019, 155, 420-428.	0.6	28
113	Comprehensive characterization of circular RNAs in ~1000 human cancer cell lines. <i>Genome Medicine</i> , 2019, 11, 55.	3.6	116
114	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , 2019, 120, 54-64.	1.3	18
115	Identification and validation of a prognostic proteomic signature for cervical cancer. <i>Gynecologic Oncology</i> , 2019, 155, 324-330.	0.6	8
116	Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking. <i>Journal of Cancer</i> , 2019, 10, 4978-4988.	1.2	3
117	Proteomics advances for precision therapy in ovarian cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 841-850.	1.3	5
118	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 642-655.	1.9	39
119	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 419-427.	4.2	46
120	Advancing Drug Development in Gynecologic Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 4874-4880.	3.2	18
121	TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. <i>Molecular and Cellular Proteomics</i> , 2019, 18, S15-S25.	2.5	61
122	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , 2019, 10, 3533-3546.	0.8	19
123	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. <i>Cancer Cell</i> , 2019, 35, 851-867.e7.	7.7	156
124	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1439-1450.	1.9	12
125	Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , 2019, 569, 503-508.	13.7	2,149
126	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. <i>Annals of Oncology</i> , 2019, 30, 597-603.	0.6	114

#	ARTICLE	IF	CITATIONS
127	Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. <i>Cancer Cell</i> , 2019, 35, 341-343.	7.7	7
128	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. <i>Nature Metabolism</i> , 2019, 1, 431-444.	5.1	158
129	Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer. <i>Molecular Cell</i> , 2019, 74, 378-392.e5.	4.5	41
130	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	2.0	39
131	GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β -catenin activity. <i>Oncogene</i> , 2019, 38, 5294-5307.	2.6	22
132	Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity. <i>PLoS ONE</i> , 2019, 14, e0205623.	1.1	17
133	Olaparib and β -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , 2019, 20, 570-580.	5.1	191
134	Breast cancer quantitative proteome and proteogenomic landscape. <i>Nature Communications</i> , 2019, 10, 1600.	5.8	152
135	Integrated transcriptomic and genomic tool Texomer profiles cancer tissues. <i>Nature Methods</i> , 2019, 16, 401-404.	9.0	7
136	Prospective Clinical Sequencing of Adult Glioma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 991-1000.	1.9	15
137	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412.	1.9	9
138	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. <i>Nature Communications</i> , 2019, 10, 716.	5.8	36
139	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. <i>Scientific Reports</i> , 2019, 9, 1853.	1.6	167
140	Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 1102-1109.	2.3	2
141	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	9
142	miRNA51b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2019, 29, 4389-4406.e10.	2.9	55
143	MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology. <i>Hepatology</i> , 2019, 70, 532-546.	3.6	28
144	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. <i>Cancer Research</i> , 2019, 79, 311-319.	0.4	404

#	ARTICLE	IF	CITATIONS
145	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 334-345.	3.2	17
146	Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations. <i>Neoplasia</i> , 2019, 21, 197-205.	2.3	19
147	State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 81-104.	12.5	736
148	Confocal Fluorescence Microscopy Platform Suitable for Rapid Evaluation of Small Fragments of Tissue in Surgical Pathology Practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 305-313.	1.2	16
149	Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1188, 251-266.	0.8	17
150	A-to-I edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 5343-5356.	3.9	46
151	Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. <i>Oncotarget</i> , 2019, 10, 2095-2111.	0.8	23
152	Combination of Ionizing Radiation with Glutaminase Inhibition Improves Treatment Response in Head and Neck Squamous Cell Carcinoma. <i>FASEB Journal</i> , 2019, 33, 495.9.	0.2	0
153	A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. <i>Cancer Cell</i> , 2018, 33, 817-828.e7.	7.7	172
154	EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. <i>Molecular Cell</i> , 2018, 70, 197-210.e7.	4.5	116
155	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. <i>Nature Communications</i> , 2018, 9, 1317.	5.8	94
156	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018, 173, 400-416.e11.	13.5	2,277
157	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	13.5	1,670
158	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018, 173, 291-304.e6.	13.5	1,718
159	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018, 173, 386-399.e12.	13.5	228
160	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	13.5	272
161	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
162	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	13.5	2,111

#	ARTICLE	IF	CITATIONS
163	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018, 173, 355-370.e14.	13.5	620
164	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018, 23, 282-296.e4.	2.9	333
165	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	2.9	407
166	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	2.9	245
167	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018, 23, 297-312.e12.	2.9	205
168	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
169	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018, 23, 181-193.e7.	2.9	683
170	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	6.6	3,706
171	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 172-180.e3.	2.9	119
172	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018, 23, 213-226.e3.	2.9	83
173	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 239-254.e6.	2.9	801
174	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018, 23, 255-269.e4.	2.9	204
175	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018, 23, 270-281.e3.	2.9	177
176	BRD4 facilitates replication stress-induced DNA damage response. <i>Oncogene</i> , 2018, 37, 3763-3777.	2.6	84
177	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	79
178	Rab25 augments cancer cell invasiveness through a β 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. <i>Experimental and Molecular Medicine</i> , 2018, 50, e435-e435.	3.2	45
179	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <i>Clinical Cancer Research</i> , 2018, 24, 2719-2731.	3.2	54
180	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	7.7	270

#	ARTICLE	IF	CITATIONS
181	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. <i>Cell Systems</i> , 2018, 6, 13-24.	2.9	327
182	Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2 δ -mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression. <i>Clinical Cancer Research</i> , 2018, 24, 1677-1690.	3.2	29
183	Ex Vivo Confocal Fluorescence Microscopy for Rapid Evaluation of Tissues in Surgical Pathology Practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 396-401.	1.2	35
184	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 379-389.	3.0	111
185	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , 2018, 9, 1777.	5.8	245
186	Credentialing Individual Samples for Proteogenomic Analysis. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1515-1530.	2.5	5
187	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018, 6, 271-281.e7.	2.9	605
188	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018, 6, 282-300.e2.	2.9	284
189	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018, 33, 706-720.e9.	7.7	400
190	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	7.7	750
191	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	7.7	396
192	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	7.7	478
193	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. <i>Cell Systems</i> , 2018, 6, 314-328.e2.	2.9	183
194	Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1245-1258.	2.5	19
195	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. <i>Cell Systems</i> , 2018, 6, 329-342.e6.	2.9	72
196	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29
197	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. <i>Cancer Cell</i> , 2018, 33, 401-416.e8.	7.7	215
198	Systematic Functional Annotation of Somatic Mutations in Cancer. <i>Cancer Cell</i> , 2018, 33, 450-462.e10.	7.7	213

#	ARTICLE	IF	CITATIONS
199	Physician interpretation of genomic test results and treatment selection. <i>Cancer</i> , 2018, 124, 966-972.	2.0	10
200	Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. <i>Clinical Cancer Research</i> , 2018, 24, 508-510.	3.2	13
201	Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	43
202	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. <i>Nature Communications</i> , 2018, 9, 4583.	5.8	44
203	Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. <i>Nature Communications</i> , 2018, 9, 5426.	5.8	11
204	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. <i>Journal of Translational Medicine</i> , 2018, 16, 358.	1.8	35
205	Modulation of the Hippo pathway and organ growth by RNA processing proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10684-10689.	3.3	13
206	Targeting gamma secretase: has progress moved up a Notch?. <i>Annals of Oncology</i> , 2018, 29, 1889-1891.	0.6	5
207	Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. <i>Nature Communications</i> , 2018, 9, 3982.	5.8	28
208	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	5.8	120
209	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	2.9	134
210	Personalized Integrated Network Modeling of the Cancer Proteome Atlas. <i>Scientific Reports</i> , 2018, 8, 14924.	1.6	14
211	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	2.3	9
212	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	7.7	422
213	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , 2018, 25, 1304-1317.e5.	2.9	329
214	Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. <i>Cell Reports</i> , 2018, 23, 2095-2106.	2.9	37
215	Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. <i>Cancer Cell</i> , 2018, 33, 985-1003.e7.	7.7	184
216	Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. <i>Cancer Letters</i> , 2018, 432, 84-92.	3.2	14

#	ARTICLE	IF	CITATIONS
217	Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. <i>Nature Communications</i> , 2018, 9, 1920.	5.8	85
218	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. <i>Clinical Cancer Research</i> , 2018, 24, 4874-4886.	3.2	60
219	Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation. <i>Trends in Biochemical Sciences</i> , 2018, 43, 576-592.	3.7	20
220	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018, 34, 211-224.e6.	7.7	623
221	BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. <i>PLoS ONE</i> , 2018, 13, e0200826.	1.1	50
222	In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. <i>Nature Communications</i> , 2018, 9, 2732.	5.8	33
223	AKT isoform-specific expression and activation across cancer lineages. <i>BMC Cancer</i> , 2018, 18, 742.	1.1	32
224	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nature Medicine</i> , 2018, 24, 556-562.	15.2	372
225	Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. <i>BMC Cancer</i> , 2018, 18, 168.	1.1	14
226	Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. <i>Oncogene</i> , 2018, 37, 4546-4561.	2.6	61
227	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , 2018, 560, 382-386.	13.7	1,836
228	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018, 19, .	2.0	30
229	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	2.9	324
230	β -catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer. <i>Oncogene</i> , 2018, 37, 5466-5475.	2.6	12
231	Cancer driver mutation prediction through Bayesian integration of multi-omic data. <i>PLoS ONE</i> , 2018, 13, e0196939.	1.1	23
232	Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer. , 2018, , .		9
233	Distinct histone modifications denote early stress-induced drug tolerance in cancer. <i>Oncotarget</i> , 2018, 9, 8206-8222.	0.8	54
234	Predicting high-risk endometrioid carcinomas using proteins. <i>Oncotarget</i> , 2018, 9, 19704-19715.	0.8	5

#	ARTICLE	IF	CITATIONS
235	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , 2017, 543, 378-384.	13.7	1,158
236	Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. <i>Cell Systems</i> , 2017, 4, 73-83.e10.	2.9	41
237	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	7.7	532
238	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. <i>Cancer Research</i> , 2017, 77, 1637-1648.	0.4	47
239	CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. <i>Modern Pathology</i> , 2017, 30, 1032-1041.	2.9	220
240	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , 2017, 31, 225-239.	7.7	190
241	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF- κ B Pathway in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 4831-4842.	3.2	33
242	Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. <i>Genome Research</i> , 2017, 27, 1112-1125.	2.4	144
243	Identifying Abundant Immunotherapy and Other Targets in Solid Tumors. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBJ /Overlo</i>	1.0	2
244	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , 2017, 3, e1600957.	4.7	10
245	Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. <i>Cancer Research</i> , 2017, 77, 3502-3512.	0.4	31
246	Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer. <i>Cancer Research</i> , 2017, 77, 3745-3757.	0.4	34
247	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. <i>JAMA Oncology</i> , 2017, 3, 1654.	3.4	208
248	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017, 169, 1327-1341.e23.	13.5	1,794
249	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , 2017, 31, 820-832.e3.	7.7	433
250	Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. <i>Bioinformatics</i> , 2017, 33, 2890-2896.	1.8	13
251	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
252	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	174

#	ARTICLE	IF	CITATIONS
253	Functional variomics and network perturbation: connecting genotype to phenotype in cancer. <i>Nature Reviews Genetics</i> , 2017, 18, 395-410.	7.7	84
254	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. <i>Breast Cancer Research</i> , 2017, 19, 44.	2.2	85
255	Integrated Molecular Characterization of Uterine Carcinosarcoma. <i>Cancer Cell</i> , 2017, 31, 411-423.	7.7	309
256	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
257	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. <i>Annals of Oncology</i> , 2017, 28, 512-518.	0.6	171
258	Role of RPL39 in Metaplastic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw292.	3.0	55
259	Precision oncology: neither a silver bullet nor a dream. <i>Pharmacogenomics</i> , 2017, 18, 1525-1539.	0.6	21
260	Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. <i>Cancer Research</i> , 2017, 77, e51-e54.	0.4	101
261	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6468-6477.	3.2	48
262	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	13.5	1,742
263	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	13.7	146
264	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. <i>Cancer Research</i> , 2017, 77, 5873-5885.	0.4	26
265	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. <i>Cancer Discovery</i> , 2017, 7, 1266-1283.	7.7	159
266	Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer. <i>Nature Communications</i> , 2017, 8, 660.	5.8	44
267	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	0.7	32
268	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Scientific Reports</i> , 2017, 7, 10240.	1.6	19
269	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. <i>Clinical Cancer Research</i> , 2017, 23, 6686-6696.	3.2	66
270	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017, 32, 204-220.e15.	7.7	642

#	ARTICLE	IF	CITATIONS
271	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2017, 32, 185-203.e13.	7.7	1,428
272	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , 2017, 21, 1953-1967.	2.9	117
273	“Personalized Cancer Therapy” A Publicly Available Precision Oncology Resource. <i>Cancer Research</i> , 2017, 77, e123-e126.	0.4	31
274	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	13.5	738
275	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. <i>Npj Systems Biology and Applications</i> , 2017, 3, 8.	1.4	55
276	Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. <i>Npj Breast Cancer</i> , 2017, 3, 18.	2.3	18
277	Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4“NDRG1 Axis. <i>Cancer Research</i> , 2017, 77, 86-99.	0.4	63
278	Neomorphic mutations create therapeutic challenges in cancer. <i>Oncogene</i> , 2017, 36, 1607-1618.	2.6	24
279	Multiplatform-based molecular subtypes of non-small-cell lung cancer. <i>Oncogene</i> , 2017, 36, 1384-1393.	2.6	118
280	Loss“of“ function screens of druggable targetome against cancer stem“like cells. <i>FASEB Journal</i> , 2017, 31, 625-635.	0.2	32
281	Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. <i>Annual Review of Medicine</i> , 2017, 68, 113-125.	5.0	34
282	RCP induces Slug expression and cancer cell invasion by stabilizing β 1 integrin. <i>Oncogene</i> , 2017, 36, 1102-1111.	2.6	36
283	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clinical Cancer Research</i> , 2017, 23, 1263-1273.	3.2	95
284	Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. <i>Oncogene</i> , 2017, 36, 1745-1752.	2.6	62
285	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. <i>Oncogene</i> , 2017, 36, 1339-1350.	2.6	39
286	Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. <i>BMC Genomics</i> , 2017, 18, 678.	1.2	24
287	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. <i>Nature Communications</i> , 2017, 8, 365.	5.8	44
288	Clinical Use of Precision Oncology Decision Support. <i>JCO Precision Oncology</i> , 2017, 2017, 1-12.	1.5	22

#	ARTICLE	IF	CITATIONS
289	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight, 2017, 2, e89760.	2.3	55
290	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight, 2017, 2, e90449.	2.3	45
291	Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts).. Journal of Clinical Oncology, 2017, 35, 9575-9575.	0.8	1
292	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. PLoS ONE, 2017, 12, e0189651.	1.1	27
293	Functional proteomic characterization of cancer cell lines. Oncoscience, 2017, 4, 41-42.	0.9	2
294	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget, 2017, 8, 41806-41814.	0.8	12
295	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget, 2017, 8, 57882-57888.	0.8	10
296	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget, 2017, 8, 106989-107001.	0.8	9
297	Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. American Journal of Cancer Research, 2017, 7, 473-483.	1.4	24
298	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	3.9	219
299	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment, 2016, 158, 441-454.	1.1	26
300	The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Review of Quality of Life in Cancer Care, 2016, 1, 231-238.	0.6	12
301	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics, 2016, 17, 394.	1.2	28
302	Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. Scientific Reports, 2016, 6, 27391.	1.6	30
303	Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. Journal of Hepatology, 2016, 65, 325-333.	1.8	56
304	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	3.2	38
305	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research, 2016, 76, 1942-1953.	0.4	77
306	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Research, 2016, 76, 2406-2418.	0.4	64

#	ARTICLE	IF	CITATIONS
307	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 159-172.	3.6	115
308	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. <i>Cell Reports</i> , 2016, 15, 1493-1504.	2.9	75
309	Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. <i>Cancer Cell</i> , 2016, 29, 711-722.	7.7	242
310	Loss of <i>ARID1A</i> Activates <i>ANXA1</i> , which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2016, 22, 5238-5248.	3.2	43
311	Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. <i>Seminars in Oncology</i> , 2016, 43, 476-483.	0.8	55
312	Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 2017-2031.	2.9	84
313	AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2563-2574.	1.9	123
314	The rise of genomic profiling in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1337-1351.	1.5	18
315	ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. <i>Cancer Research</i> , 2016, 76, 7168-7180.	0.4	53
316	Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. <i>Scientific Reports</i> , 2016, 6, 29721.	1.6	27
317	Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. <i>Journal of Biological Chemistry</i> , 2016, 291, 25247-25254.	1.6	29
318	Functional annotation of rare gene aberration drivers of pancreatic cancer. <i>Nature Communications</i> , 2016, 7, 10500.	5.8	58
319	Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. <i>Cancer & Metabolism</i> , 2016, 4, 12.	2.4	57
320	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
321	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , 2016, 14, 2476-2489.	2.9	298
322	Targeting therapeutic liabilities engendered by <i>PIK3R1</i> mutations for cancer treatment. <i>Pharmacogenomics</i> , 2016, 17, 297-307.	0.6	36
323	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. <i>Cell</i> , 2016, 164, 293-309.	13.5	399
324	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701

#	ARTICLE	IF	CITATIONS
325	Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines. <i>International Journal of Oncology</i> , 2016, 48, 67-72.	1.4	7
326	Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 513-523.	3.2	25
327	Reply to M.P. Decatris et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 886-886.	0.8	1
328	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. <i>Cancer Research</i> , 2016, 76, 2720-2730.	0.4	33
329	Inferring causal molecular networks: empirical assessment through a community-based effort. <i>Nature Methods</i> , 2016, 13, 310-318.	9.0	209
330	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3764-3773.	3.2	733
331	Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. <i>Cancer Research</i> , 2016, 76, 2662-2674.	0.4	31
332	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. <i>Molecular Cancer Research</i> , 2016, 14, 278-286.	1.5	48
333	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 1592-1602.	3.2	108
334	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1699-1712.	3.2	95
335	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	13.9	1,040
336	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 935-947.	3.2	42
337	Thematic Review Series: Phospholipases: Central Role in Lipid Signaling and Disease Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. <i>Journal of Lipid Research</i> , 2016, 57, 25-35.	2.0	41
338	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016, 7, 76362-76373.	0.8	22
339	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. <i>Oncotarget</i> , 2016, 7, 27185-27198.	0.8	37
340	Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. <i>Oncotarget</i> , 2016, 7, 40252-40265.	0.8	35
341	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. <i>AIMS Medical Science</i> , 2016, 3, 386-416.	0.2	3
342	The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism. <i>Blood</i> , 2016, 128, 2757-2757.	0.6	4

#	ARTICLE	IF	CITATIONS
343	Verteporfin inhibits YAP function through up-regulating 14-3-3 β sequestering YAP in the cytoplasm. American Journal of Cancer Research, 2016, 6, 27-37.	1.4	96
344	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. Npj Systems Biology and Applications, 2015, 1, 15001.	1.4	3
345	â€œInjunctivitisâ€™. International Journal of Police Science and Management, 2015, 17, 128-133.	0.8	1
346	Retrospective review of MET gene mutations. Oncoscience, 2015, 2, 533-541.	0.9	30
347	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	30
348	Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies. Cancer Cell, 2015, 27, 354-369.	7.7	177
349	p85 β neomorphic mutants: splitting away from the canonical path. Molecular and Cellular Oncology, 2015, 2, e983388.	0.3	1
350	Identification of Variant-Specific Functions of <i>PIK3CA</i> by Rapid Phenotyping of Rare Mutations. Cancer Research, 2015, 75, 5341-5354.	0.4	130
351	RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 788-793.	1.8	65
352	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	1.5	85
353	The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discovery Today, 2015, 20, 1433-1438.	3.2	58
354	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	7.7	696
355	Association of Somatic Mutations of <i>ADAMTS</i> Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncology, 2015, 1, 486.	3.4	32
356	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
357	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discovery, 2015, 5, 752-767.	7.7	361
358	PTEN loss is a contextâ€‘dependent outcome determinant in obese and nonâ€‘obese endometrioid endometrial cancer patients. Molecular Oncology, 2015, 9, 1694-1703.	2.1	47
359	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. Molecular Cancer, 2015, 14, 29.	7.9	15
360	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Medicine, 2015, 7, 21.	3.6	34

#	ARTICLE	IF	CITATIONS
361	Î±-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive Migration. <i>Cancer Research</i> , 2015, 75, 203-215.	0.4	160
362	The PI3K/AKT Pathway and Renal Cell Carcinoma. <i>Journal of Genetics and Genomics</i> , 2015, 42, 343-353.	1.7	267
363	Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. <i>Cell Cycle</i> , 2015, 14, 2323-2332.	1.3	38
364	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	168
365	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015, 21, 3480-3491.	3.2	48
366	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.4	68
367	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	7.7	426
368	Large-Scale Drug Screens Support Precision Medicine. <i>Cancer Discovery</i> , 2015, 5, 1130-1132.	7.7	10
369	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2015, 144, 713-721.	0.4	34
370	Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women. <i>Cancer Prevention Research</i> , 2015, 8, 912-921.	0.7	25
371	TransVar: a multilevel variant annotator for precision genomics. <i>Nature Methods</i> , 2015, 12, 1002-1003.	9.0	67
372	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2753-2762.	0.8	372
373	Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. <i>Nature Communications</i> , 2015, 6, 7926.	5.8	98
374	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. <i>Cancer Cell</i> , 2015, 28, 529-540.	7.7	601
375	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	13.5	1,485
376	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 238.	3.4	44
377	Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women. <i>Cancer Prevention Research</i> , 2015, 8, 922-931.	0.7	33
378	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. <i>Nature Communications</i> , 2015, 6, 7419.	5.8	149

#	ARTICLE	IF	CITATIONS
379	Development of a robust classifier for quality control of reverse-phase protein arrays. <i>Bioinformatics</i> , 2015, 31, 912-918.	1.8	43
380	Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1688-1698.	3.2	990
381	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. <i>Genome Research</i> , 2015, 25, 257-267.	2.4	94
382	In silico prediction of physical protein interactions and characterization of interactome orphans. <i>Nature Methods</i> , 2015, 12, 79-84.	9.0	148
383	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.3	138
384	Death-associated protein kinase 1 promotes growth of p53-mutant cancers. <i>Journal of Clinical Investigation</i> , 2015, 125, 2707-2720.	3.9	49
385	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 1459-1470.	3.9	106
386	Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or <i>BRCA1/2</i> mutation-associated breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1018-1018.	0.8	3
387	Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1510-1510.	0.8	4
388	Clinical characteristics and survival outcomes in <i>BRCA1</i> -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5526-5526.	0.8	2
389	Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in <i>BRCA1/2</i> , mutations/deletions in <i>PTEN</i> or <i>PTEN</i> loss, a homologous recombination defect, mutations/deletions in other <i>BRCA</i> pathway genes and germline mutation S in <i>BRCA1/2</i> (not breast or) Tj ETQq1 1 0:784314 ⁵ tgBT /Over	0.8	5
390	Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0133219.	1.1	19
391	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. <i>PLoS ONE</i> , 2015, 10, e0136851.	1.1	54
392	Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers. <i>PLoS ONE</i> , 2015, 10, e0140072.	1.1	9
393	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. <i>Oncotarget</i> , 2015, 6, 1327-1339.	0.8	50
394	Functional consequence of the <i>MET-T</i> 1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614.	0.8	34
395	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.	0.8	41
396	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. <i>Oncotarget</i> , 2015, 6, 41736-41749.	0.8	22

#	ARTICLE	IF	CITATIONS
397	Regulation of the PI3K pathway through a p85 α monomer \leftrightarrow homodimer equilibrium. <i>ELife</i> , 2015, 4, e06866.	2.8	65
398	Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. <i>ELife</i> , 2015, 4, .	2.8	79
399	Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22168-e22168.	0.8	0
400	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3612-3612.	0.8	0
401	Clinical outcomes based on multigene profiling in metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1524-1524.	0.8	0
402	Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22163-e22163.	0.8	0
403	Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6016-6016.	0.8	0
404	Targeting ncRNAs in the 3q26.2 amplicon. <i>Oncoscience</i> , 2015, 2, 671-672.	0.9	2
405	Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib. <i>Blood</i> , 2015, 126, 1386-1386.	0.6	0
406	Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. <i>American Journal of Cancer Research</i> , 2015, 5, 928-44.	1.4	12
407	Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. <i>American Journal of Cancer Research</i> , 2015, 5, 1265-80.	1.4	9
408	Spatial Normalization of Reverse Phase Protein Array Data. <i>PLoS ONE</i> , 2014, 9, e97213.	1.1	23
409	AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e100827.	1.1	11
410	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 745-753.	1.2	46
411	Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1 α -Driven Regulation of cAMP Phosphodiesterase-4D. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2463-2473.	1.9	16
412	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1114-1119.	3.3	86
413	A curated census of autophagy-modulating proteins and small molecules. <i>Autophagy</i> , 2014, 10, 1316-1326.	4.3	29
414	Unraveling the regulatory connections between two controllers of breast cancer cell fate. <i>Nucleic Acids Research</i> , 2014, 42, 6839-6849.	6.5	10

#	ARTICLE	IF	CITATIONS
415	<i>Mig-6</i> Suppresses Endometrial Cancer Associated with <i>Pten</i> Deficiency and ERK Activation. <i>Cancer Research</i> , 2014, 74, 7371-7382.	0.4	40
416	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. <i>Cancer Research</i> , 2014, 74, 4845-4852.	0.4	148
417	Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors. <i>Cancer Cell</i> , 2014, 26, 479-494.	7.7	73
418	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. <i>Cell</i> , 2014, 159, 676-690.	13.5	2,318
419	AKT-dependent phosphorylation of Niban regulates nucleophosmin and MDM2-mediated p53 stability and cell apoptosis. <i>EMBO Reports</i> , 2014, 15, 1000-1000.	2.0	1
420	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. <i>Cancer Cell</i> , 2014, 26, 863-879.	7.7	46
421	A Bayesian hierarchical model for inference across related reverse phase protein arrays experiments. <i>Journal of Applied Statistics</i> , 2014, 41, 2483-2492.	0.6	0
422	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 α and Oxidative Phosphorylation in Melanoma. <i>Cancer Research</i> , 2014, 74, 7037-7047.	0.4	161
423	Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1625-1643.	2.5	152
424	Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations. <i>Clinical Cancer Research</i> , 2014, 20, 404-412.	3.2	31
425	A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of <i>Pten</i> and <i>Lkb1</i> Is Highly Responsive to mTOR Inhibition. <i>Cancer Research</i> , 2014, 74, 15-23.	0.4	57
426	Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 189-201.	1.1	7
427	Cancer Systems Biology: a peek into the future of patient care?. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 167-176.	12.5	159
428	Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. <i>Cancer Research</i> , 2014, 74, 3127-3136.	0.4	20
429	Bias from removing read duplication in ultra-deep sequencing experiments. <i>Bioinformatics</i> , 2014, 30, 1073-1080.	1.8	39
430	Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	182
431	Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2300-2311.	3.2	85
432	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. <i>European Journal of Cancer</i> , 2014, 50, 3003-3010.	1.3	73

#	ARTICLE	IF	CITATIONS
433	Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 316-323.	1.1	18
434	RADical Response Puts an Exceptional Responder in CHKmate: A Synthetic Lethal Curative Response to DNA-Damaging Chemotherapy?. <i>Cancer Discovery</i> , 2014, 4, 988-990.	7.7	5
435	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. <i>Cancer Cell</i> , 2014, 26, 222-234.	7.7	71
436	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1690-1704.	2.5	323
437	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. <i>Cell</i> , 2014, 158, 929-944.	13.5	1,242
438	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2738-2750.	1.9	72
439	A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. <i>Cancer Cell</i> , 2014, 26, 344-357.	7.7	361
440	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , 2014, 16, 406.	2.2	267
441	Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 381-387.	1.1	21
442	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , 2014, 32, 644-652.	9.4	257
443	Genome-wide transcriptome profiling of homologous recombination DNA repair. <i>Nature Communications</i> , 2014, 5, 3361.	5.8	182
444	Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2014, 26, 7-9.	7.7	8
445	Definition of PKC-Î±, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4822-4835.	0.4	61
446	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1382-1389.	1.9	104
447	Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3870-3883.	3.2	47
448	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014, 5, 3887.	5.8	456
449	YB-1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal-Like Breast Cancer. <i>Stem Cells</i> , 2014, 32, 1437-1450.	1.4	37
450	Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. <i>Molecular Cell</i> , 2014, 54, 960-974.	4.5	196

#	ARTICLE	IF	CITATIONS
451	LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. <i>Journal of Clinical Investigation</i> , 2014, 124, 5490-5502.	3.9	34
452	A Comprehensive Comparison of Normalization Methods for Loading Control and Variance Stabilization of Reverse-Phase Protein Array Data. <i>Cancer Informatics</i> , 2014, 13, CIN.S13329.	0.9	19
453	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. <i>Journal of Clinical Investigation</i> , 2014, 124, 2611-2625.	3.9	110
454	Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. <i>PLoS ONE</i> , 2014, 9, e115383.	1.1	362
455	Shrewd AKT regulation to survive. <i>Oncoscience</i> , 2014, 1, 113-114.	0.9	5
456	Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. <i>Oncotarget</i> , 2014, 5, 9049-9064.	0.8	20
457	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. <i>Oncotarget</i> , 2014, 5, 8544-8557.	0.8	56
458	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. <i>Anticancer Research</i> , 2014, 34, 811-817.	0.5	46
459	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. <i>Discovery Medicine</i> , 2014, 17, 101-14.	0.5	41
460	Frequency of mesenchymal-epithelial transition factor gene (<i>MET</i>) and the catalytic subunit of phosphoinositide-3-kinase (<i>PIK3CA</i>) copy number elevation and correlation with outcome in patients with early stage breast cancer. <i>Cancer</i> , 2013, 119, 7-15.	2.0	49
461	EV11 splice variants modulate functional responses in ovarian cancer cells. <i>Molecular Oncology</i> , 2013, 7, 647-668.	2.1	38
462	Mask Is Required for the Activity of the Hippo Pathway Effector Yki/YAP. <i>Current Biology</i> , 2013, 23, 229-235.	1.8	71
463	BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. <i>Molecular Oncology</i> , 2013, 7, 567-579.	2.1	121
464	Inferring tumour purity and stromal and immune cell admixture from expression data. <i>Nature Communications</i> , 2013, 4, 2612.	5.8	5,788
465	PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. <i>Cell</i> , 2013, 155, 397-409.	13.5	429
466	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	13.5	3,979
467	Repurposing the Pap Smear: One Step Closer to Gynecologic Cancer Screening. <i>Science Translational Medicine</i> , 2013, 5, 167ps1.	5.8	5
468	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , 2013, 45, 1113-1120.	9.4	6,265

#	ARTICLE	IF	CITATIONS
469	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. <i>Cancer & Metabolism</i> , 2013, 1, 18.	2.4	44
470	Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10% weight loss in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 119-132.	1.1	59
471	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. <i>Clinical Cancer Research</i> , 2013, 19, 657-667.	3.2	250
472	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. <i>Cancer Discovery</i> , 2013, 3, 761-769.	7.7	505
473	Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals. <i>Molecular Cell</i> , 2013, 49, 249-261.	4.5	421
474	High stearyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 319-327.	1.1	90
475	The Impact of Tumor Heterogeneity on Patient Treatment Decisions. <i>Clinical Chemistry</i> , 2013, 59, 38-40.	1.5	10
476	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
477	EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol. <i>Molecular Oncology</i> , 2013, 7, 121-129.	2.1	32
478	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	3.2	848
479	Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. <i>Hepatology</i> , 2013, 58, 182-191.	3.6	79
480	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013, 497, 67-73.	13.7	4,075
481	Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. <i>Molecular Oncology</i> , 2013, 7, 704-718.	2.1	77
482	AMPK: A Contextual Oncogene or Tumor Suppressor?. <i>Cancer Research</i> , 2013, 73, 2929-2935.	0.4	220
483	Building a Personalized Medicine Infrastructure at a Major Cancer Center. <i>Journal of Clinical Oncology</i> , 2013, 31, 1849-1857.	0.8	101
484	TCPA: a resource for cancer functional proteomics data. <i>Nature Methods</i> , 2013, 10, 1046-1047.	9.0	446
485	BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation. <i>Science Signaling</i> , 2013, 6, ra2.	1.6	39
486	Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. <i>Modern Pathology</i> , 2013, 26, 544-552.	2.9	13

#	ARTICLE	IF	CITATIONS
487	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. <i>PLoS Computational Biology</i> , 2013, 9, e1003290.	1.5	128
488	Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6322-6328.	3.2	171
489	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2171-2182.	0.9	16
490	The Successes and Failures of Policing Animal Rights Extremism in the UK 2004â€“2010. <i>International Journal of Police Science and Management</i> , 2013, 15, 30-44.	0.8	6
491	Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8. <i>Cancer Research</i> , 2013, 73, 3470-3480.	0.4	342
492	Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3703-3713.	3.2	119
493	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. <i>Cancer Research</i> , 2013, 73, 4885-4897.	0.4	394
494	Modeling precision treatment of breast cancer. <i>Genome Biology</i> , 2013, 14, R110.	13.9	264
495	Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines. <i>PLoS ONE</i> , 2013, 8, e60339.	1.1	6
496	Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2013, 8, e70608.	1.1	19
497	Predicting time to ovarian carcinoma recurrence using protein markers. <i>Journal of Clinical Investigation</i> , 2013, 123, 3740-50.	3.9	46
498	Predicting time to ovarian carcinoma recurrence using protein markers. <i>Journal of Clinical Investigation</i> , 2013, 123, 5410-5410.	3.9	24
499	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. <i>PLoS ONE</i> , 2013, 8, e77945.	1.1	104
500	High risk CNIs, race and early stage breast cancer. <i>FASEB Journal</i> , 2013, 27, 214.3.	0.2	0
501	Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKCâ†± Invasive Signaling Axis. <i>Science Signaling</i> , 2012, 5, ra66.	1.6	69
502	Rab25 in cancer: a brief update. <i>Biochemical Society Transactions</i> , 2012, 40, 1404-1408.	1.6	58
503	LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. <i>PLoS Genetics</i> , 2012, 8, e1002538.	1.5	35
504	Agents That Stabilize Mutated von Hippelâ€“Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis. <i>Journal of Biomolecular Screening</i> , 2012, 17, 572-580.	2.6	23

#	ARTICLE	IF	CITATIONS
505	Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models <i>in Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2012, 18, 5911-5923.	3.2	69
506	PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. <i>Clinical Cancer Research</i> , 2012, 18, 1777-1789.	3.2	191
507	Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. <i>Journal of Experimental Medicine</i> , 2012, 209, 925-933.	4.2	143
508	Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57 ^{Kip2} . <i>Science Signaling</i> , 2012, 5, ra19.	1.6	76
509	Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. <i>Modern Pathology</i> , 2012, 25, 699-708.	2.9	145
510	Autotaxin and Its Product Lysophosphatidic Acid Suppress Brown Adipose Differentiation and Promote Diet-Induced Obesity in Mice. <i>Molecular Endocrinology</i> , 2012, 26, 786-797.	3.7	59
511	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. <i>Journal of Experimental Medicine</i> , 2012, 209, 679-696.	4.2	309
512	Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2483-2494.	1.9	67
513	Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5816-5828.	3.2	135
514	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. <i>Cancer Discovery</i> , 2012, 2, 798-811.	7.7	432
515	Dissecting the Complexity of Personalized Therapy for Ovarian Cancer. <i>Cancer Discovery</i> , 2012, 2, 16-18.	7.7	32
516	Sparse Bayesian graphical models for RPPA time course data. , 2012, 2012, 113-117.		3
517	Lysophosphatidic Acid Signaling Protects Pulmonary Vasculature From Hypoxia-Induced Remodeling, Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 24-32.	1.1	32
518	AKT-dependent phosphorylation of Niban regulates nucleophosmin and MDM2-mediated p53 stability and cell apoptosis. <i>EMBO Reports</i> , 2012, 13, 554-560.	2.0	59
519	Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1109-1119.	3.2	62
520	Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling. <i>Cell</i> , 2012, 150, 780-791.	13.5	1,310
521	cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes. <i>Clinical Cancer Research</i> , 2012, 18, 2269-2277.	3.2	108
522	Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2278-2289.	3.2	67

#	ARTICLE	IF	CITATIONS
523	EGR1 and the ERK/ERF axis drive mammary cell migration in response to EGF. <i>FASEB Journal</i> , 2012, 26, 1582-1592.	0.2	88
524	Targeting the Hepatocyte Growth Factor/cMET Axis in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 3287-3296.	0.8	258
525	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. <i>Genome Research</i> , 2012, 22, 2120-2129.	2.4	206
526	Bioinformatics and systems biology. <i>Molecular Oncology</i> , 2012, 6, 147-154.	2.1	22
527	Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival. <i>Clinical Cancer Research</i> , 2012, 18, 1257-1267.	3.2	77
528	Lysophosphatidic Acid Induces Lymphangiogenesis and IL-8 Production in Vitro in Human Lymphatic Endothelial Cells. <i>American Journal of Pathology</i> , 2012, 180, 2170-2181.	1.9	32
529	Overcoming implementation challenges of personalized cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 542-548.	12.5	115
530	Subtype and pathway specific responses to anticancer compounds in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2724-2729.	3.3	417
531	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. <i>Proteome Science</i> , 2012, 10, 56.	0.7	59
532	An emerging toolkit for targeted cancer therapies: Table 1.. <i>Genome Research</i> , 2012, 22, 177-182.	2.4	21
533	Systematic analysis of genotype-specific drug responses in cancer. <i>International Journal of Cancer</i> , 2012, 131, 2456-2464.	2.3	28
534	Detection algorithm for the validation of human cell lines. <i>International Journal of Cancer</i> , 2012, 131, E1024-30.	2.3	13
535	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	15.2	219
536	Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells. <i>Cancer Cell</i> , 2012, 21, 227-239.	7.7	344
537	A Time-Series DDP for Functional Proteomics Profiles. <i>Biometrics</i> , 2012, 68, 859-868.	0.8	18
538	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 47-53.	0.6	74
539	Interactions between tumor cells and microenvironment in breast cancer: A new opportunity for targeted therapy. <i>Cancer Science</i> , 2012, 103, 400-407.	1.7	18
540	Reconstruction of nuclear receptor network reveals that <i>NR2E3</i> is a novel upstream regulator of <i>ESR1</i> in breast cancer. <i>EMBO Molecular Medicine</i> , 2012, 4, 52-67.	3.3	42

#	ARTICLE	IF	CITATIONS
541	Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. <i>EMBO Molecular Medicine</i> , 2012, 4, 125-141.	3.3	71
542	Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 377-385.	1.2	55
543	Abortive Autophagy Induces Endoplasmic Reticulum Stress and Cell Death in Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e39400.	1.1	35
544	Somatic Mutations of PIK3R1 Promote Gliomagenesis. <i>PLoS ONE</i> , 2012, 7, e49466.	1.1	49
545	A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6773-6784.	0.4	138
546	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. <i>Nature Medicine</i> , 2011, 17, 1116-1120.	15.2	231
547	DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance. <i>Neoplasia</i> , 2011, 13, 1069-1075.	2.3	108
548	Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. <i>Nature Medicine</i> , 2011, 17, 1498-1503.	15.2	1,740
549	Astrocytes Upregulate Survival Genes in Tumor Cells and Induce Protection from Chemotherapy. <i>Neoplasia</i> , 2011, 13, 286-298.	2.3	224
550	Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. <i>Molecular Cell</i> , 2011, 42, 524-535.	4.5	93
551	Rab GTPases implicated in inherited and acquired disorders. <i>Seminars in Cell and Developmental Biology</i> , 2011, 22, 57-68.	2.3	82
552	Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer. <i>PLoS ONE</i> , 2011, 6, e23543.	1.1	38
553	Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer. <i>PLoS ONE</i> , 2011, 6, e24662.	1.1	105
554	Androgen Regulation of 5 α -Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention. <i>PLoS ONE</i> , 2011, 6, e28840.	1.1	52
555	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
556	Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 117-118.	3.6	27
557	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. <i>Clinical Proteomics</i> , 2011, 8, 11.	1.1	85
558	Benzyl and Naphthalene Methylphosphonic Acid Inhibitors of Autotaxin with Anti-Invasive and Anti-Metastatic Activity. <i>ChemMedChem</i> , 2011, 6, 922-935.	1.6	56

#	ARTICLE	IF	CITATIONS
559	Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. <i>Cancer Research</i> , 2011, 71, 1871-1882.	0.4	185
560	ER±-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. <i>Cancer Discovery</i> , 2011, 1, 338-351.	7.7	284
561	HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 4412-4422.	0.4	159
562	Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17456-17461.	3.3	116
563	<i>ZNF668</i> Functions as a Tumor Suppressor by Regulating p53 Stability and Function in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6524-6534.	0.4	26
564	A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 2024-2034.	3.2	88
565	Incidence and Outcome of <i>BRCA</i> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1082-1089.	3.2	487
566	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1093-1101.	1.9	204
567	Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2350-2362.	1.9	219
568	High Frequency of <i>PIK3R1</i> and <i>PIK3R2</i> Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. <i>Cancer Discovery</i> , 2011, 1, 170-185.	7.7	419
569	Modulation of autophagy and its potential for cancer therapy. <i>Drugs of the Future</i> , 2011, 36, 919.	0.0	1
570	Small Molecule Inhibitors of HER2 Inhibit Proliferative Signaling and Promote Apoptosis in Ph+ ALL. <i>Blood</i> , 2011, 118, 1397-1397.	0.6	0
571	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. <i>Cell Cycle</i> , 2010, 9, 140-146.	1.3	21
572	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1894-1904.	0.5	57
573	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. <i>Clinical Proteomics</i> , 2010, 6, 129-151.	1.1	203
574	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. <i>Biochemical Pharmacology</i> , 2010, 79, 842-852.	2.0	20
575	The Rebirth of a Phoenix: Ovarian Cancers Are Addicted to ErbB-3. <i>Cancer Cell</i> , 2010, 17, 217-218.	7.7	21
576	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. <i>Cancer Cell</i> , 2010, 18, 423-435.	7.7	129

#	ARTICLE	IF	CITATIONS
577	Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 7525-7528.	1.0	24
578	Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges. <i>Journal of Oncology</i> , 2010, 2010, 1-20.	0.6	108
579	Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase. <i>PLoS ONE</i> , 2010, 5, e9910.	1.1	38
580	Nicotinic Acetylcholine Receptor Region on Chromosome 15q25 and Lung Cancer Risk Among African Americans: A Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1199-1205.	3.0	62
581	CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis. <i>Clinical Cancer Research</i> , 2010, 16, 3875-3886.	3.2	152
582	Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF- β 2 Pathway Signaling Indicates Response to Primary Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 2852-2860.	3.2	58
583	Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 7684-7689.	0.4	17
584	Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. <i>Clinical Cancer Research</i> , 2010, 16, 3171-3181.	3.2	106
585	Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 257-267.	1.9	81
586	<i>PIK3CA</i> mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10208-10213.	3.3	324
587	Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation. <i>Cancer Research</i> , 2010, 70, 6477-6485.	0.4	54
588	Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 3287-3298.	0.4	151
589	ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4153-4158.	3.3	628
590	Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5012-5017.	3.3	149
591	Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2770-2784.	1.9	59
592	Are oncogenes sufficient to cause human cancer?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20599-20600.	3.3	7
593	Somatic Mutations in <i>BRCA1</i> and <i>BRCA2</i> Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3570-3576.	0.8	342
594	Future of Personalized Medicine in Oncology: A Systems Biology Approach. <i>Journal of Clinical Oncology</i> , 2010, 28, 2777-2783.	0.8	223

#	ARTICLE	IF	CITATIONS
595	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 103-107.	1.0	30
596	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R40.	2.2	211
597	Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis. <i>Cancer Research</i> , 2010, 70, 6704-6714.	0.4	198
598	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor- positive human breast cancer. <i>Journal of Clinical Investigation</i> , 2010, 120, 2406-2413.	3.9	447
599	PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival. <i>PLoS ONE</i> , 2010, 5, e11729.	1.1	67
600	Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010, 1, 1-10.	0.4	19
601	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. <i>Cancer Research</i> , 2009, 69, 4116-4124.	0.4	768
602	Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and Thrombosis. <i>Journal of Biological Chemistry</i> , 2009, 284, 7385-7394.	1.6	127
603	3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma. <i>Cancer Research</i> , 2009, 69, 6299-6306.	0.4	126
604	A Systems Approach to Analysis of Molecular Complexity in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 417-419.	3.2	18
605	Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. <i>Cancer Research</i> , 2009, 69, 4192-4201.	0.4	164
606	Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 2872-2878.	3.2	62
607	Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth <i>In vivo</i> and Bypass Pathways Are Activated in AZD0530-Resistant Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3396-3405.	3.2	60
608	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 521-532.	1.9	46
609	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. <i>Journal of Clinical Oncology</i> , 2009, 27, 1235-1242.	0.8	63
610	Cetuximab Attenuates Metastasis and u-PAR Expression in Non-Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity. <i>Cancer Research</i> , 2009, 69, 2461-2470.	0.4	28
611	ATX-LPA receptor axis in inflammation and cancer. <i>Cell Cycle</i> , 2009, 8, 3695-3701.	1.3	95
612	Î2-Arrestin/Ral Signaling Regulates Lysophosphatidic Acid-Mediated Migration and Invasion of Human Breast Tumor Cells. <i>Molecular Cancer Research</i> , 2009, 7, 1064-1077.	1.5	129

#	ARTICLE	IF	CITATIONS
613	Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2079-2085.	1.9	178
614	Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance. <i>Cancer Research</i> , 2009, 69, 143-150.	0.4	273
615	Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression. <i>Cancer Research</i> , 2009, 69, 5057-5064.	0.4	154
616	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6852-6861.	3.2	105
617	Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2472-2478.	3.2	185
618	Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1157-1168.	1.9	83
619	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3654-3662.	3.2	121
620	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 7538-7546.	3.2	221
621	Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition. <i>Cancer Research</i> , 2009, 69, 565-572.	0.4	340
622	Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function. <i>Cancer Cell</i> , 2009, 15, 304-314.	7.7	175
623	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. <i>Cancer Cell</i> , 2009, 15, 539-550.	7.7	332
624	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. <i>Cancer Cell</i> , 2009, 16, 21-32.	7.7	472
625	Systems biology of breast cancer. <i>Current Breast Cancer Reports</i> , 2009, 1, 238-245.	0.5	2
626	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2009, 41, 991-995.	9.4	321
627	Oxygen sensor boosts growth factor signaling. <i>Nature Medicine</i> , 2009, 15, 246-247.	15.2	21
628	Cadherin endocytosis. <i>Nature Reviews Cancer</i> , 2009, 9, 143-143.	12.8	27
629	The biology of ovarian cancer: new opportunities for translation. <i>Nature Reviews Cancer</i> , 2009, 9, 415-428.	12.8	1,172
630	The Emerging Role of the RAB25 Small GTPase in Cancer. <i>Traffic</i> , 2009, 10, 1561-1568.	1.3	78

#	ARTICLE	IF	CITATIONS
631	PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth. <i>American Journal of Pathology</i> , 2009, 174, 1869-1879.	1.9	43
632	Functional proteomic profiling of AML predicts response and survival. <i>Blood</i> , 2009, 113, 154-164.	0.6	235
633	Genomic amplicons target vesicle recycling in breast cancer. <i>Journal of Clinical Investigation</i> , 2009, 119, 2123-7.	3.9	34
634	Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis. <i>PLoS ONE</i> , 2009, 4, e5583.	1.1	41
635	Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2009, 2, 289-99.	1.3	20
636	Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19 levels in pancreatic cancer. <i>Proteomics</i> , 2008, 8, 3051-3060.	1.3	84
637	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. <i>Molecular Carcinogenesis</i> , 2008, 47, 701-706.	1.3	249
638	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , 2008, 10, 138-148.	4.6	590
639	Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. <i>Nature Genetics</i> , 2008, 40, 616-622.	9.4	1,189
640	Derailed endocytosis: an emerging feature of cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 835-850.	12.8	652
641	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. <i>Gynecologic Oncology</i> , 2008, 108, 652-657.	0.6	21
642	Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PCa prostate cancer cells. <i>Molecular Oncology</i> , 2008, 2, 54-69.	2.1	35
643	Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: A role in ovarian pathogenesis. <i>Molecular Oncology</i> , 2008, 2, 164-181.	2.1	25
644	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 6084-6091.	0.4	916
645	AMP-Activated Protein Kinase Signaling Results in Cytoplasmic Sequestration of p27. <i>Cancer Research</i> , 2008, 68, 6496-6506.	0.4	55
646	Cancer Stem Cells Contribute to Cisplatin Resistance in <i>Brca1/p53</i> -Mediated Mouse Mammary Tumors. <i>Cancer Research</i> , 2008, 68, 3243-3250.	0.4	292
647	Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. <i>Autophagy</i> , 2008, 4, 467-475.	4.3	126
648	Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model. <i>Cancer Research</i> , 2008, 68, 7966-7974.	0.4	95

#	ARTICLE	IF	CITATIONS
649	Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. <i>Journal of Cell Science</i> , 2008, 121, 664-674.	1.2	72
650	Homozygous deletion of glycogen synthase kinase 3 β bypasses senescence allowing Ras transformation of primary murine fibroblasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5248-5253.	3.3	22
651	Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C α Raf and B α Raf isoforms by FGFR and MC1R. <i>FASEB Journal</i> , 2008, 22, 1393-1403.	0.2	18
652	A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy. <i>Cancer Prevention Research</i> , 2008, 1, 577-587.	0.7	51
653	A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. <i>Cancer Research</i> , 2008, 68, 206-215.	0.4	284
654	Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45 β . <i>Cancer Research</i> , 2008, 68, 2895-2903.	0.4	52
655	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 3917-29.	3.9	370
656	Exploratory Analysis of the Copy Number Alterations in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2008, 3, e4076.	1.1	34
657	Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency. <i>Clinical Cancer Research</i> , 2007, 13, 5883-5888.	3.2	195
658	Telomere 3 α overhang α -specific DNA oligonucleotides induce autophagy in malignant glioma cells. <i>FASEB Journal</i> , 2007, 21, 2918-2930.	0.2	57
659	Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. <i>Cancer Research</i> , 2007, 67, 5779-5788.	0.4	107
660	Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 3074-3084.	0.4	113
661	Activation of Integrin-Linked Kinase Is a Critical Prosurvival Pathway Induced in Leukemic Cells by Bone Marrow α -Derived Stromal Cells. <i>Cancer Research</i> , 2007, 67, 684-694.	0.4	178
662	Pharmacodynamic Markers of Perifosine Efficacy. <i>Clinical Cancer Research</i> , 2007, 13, 7421-7431.	3.2	116
663	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1414-1424.	1.9	73
664	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. <i>Carcinogenesis</i> , 2007, 28, 174-182.	1.3	62
665	Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab. <i>Cancer Research</i> , 2007, 67, 8240-8247.	0.4	149
666	Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1593-1598.	3.3	91

#	ARTICLE	IF	CITATIONS
667	Phosphorylation of β -Catenin by AKT Promotes β -Catenin Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 2007, 282, 11221-11229.	1.6	740
668	Non-parametric quantification of protein lysate arrays. <i>Bioinformatics</i> , 2007, 23, 1986-1994.	1.8	193
669	Rab25 Associates with β 1 Integrin to Promote Invasive Migration in 3D Microenvironments. <i>Developmental Cell</i> , 2007, 13, 496-510.	3.1	369
670	Amplification of <i>PVT1</i> Contributes to the Pathophysiology of Ovarian and Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5745-5755.	3.2	345
671	Liquid Chromatography Mass Spectrometry for Quantifying Plasma Lysophospholipids: Potential Biomarkers for Cancer Diagnosis. <i>Methods in Enzymology</i> , 2007, 433, 1-25.	0.4	85
672	The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. <i>Nature Cell Biology</i> , 2007, 9, 218-224.	4.6	782
673	A module of negative feedback regulators defines growth factor signaling. <i>Nature Genetics</i> , 2007, 39, 503-512.	9.4	506
674	A New Mutational activation in the PI3K Pathway. <i>Cancer Cell</i> , 2007, 12, 104-107.	7.7	230
675	A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. <i>Cancer Cell</i> , 2007, 12, 395-402.	7.7	1,471
676	Src promotes estrogen-dependent estrogen receptor β proteolysis in human breast cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2205-2215.	3.9	76
677	Overexpression of the Plasma Lysophospholipase D Autotaxin Reveals a Novel Pathway for Regulation of Hemostasis in Mice.. <i>Blood</i> , 2007, 110, 3649-3649.	0.6	2
678	Protein Expression Signatures Determined by Reverse Phase Proteins Arrays (RPPA) Accurately Predict FLT3-ITD Mutation Status in AML.. <i>Blood</i> , 2007, 110, 2398-2398.	0.6	0
679	mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. <i>Cancer Research</i> , 2006, 66, 1500-1508.	0.4	2,329
680	Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine. <i>Molecular Pharmacology</i> , 2006, 70, 1045-1052.	1.0	48
681	G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. <i>Blood</i> , 2006, 107, 1847-1856.	0.6	126
682	Data integration gets 'Sloppy'. <i>Nature Biotechnology</i> , 2006, 24, 1070-1071.	9.4	17
683	Ovarian Cancer: Identification of remodeling and spacing factor 1 (<i>rsf-1</i> , <i>HBXAP</i>) at chromosome 11q13 as a putative oncogene in ovarian cancer. <i>European Journal of Human Genetics</i> , 2006, 14, 381-383.	1.4	12
684	Molecular screening for breast cancer prevention, early detection, and treatment planning: Combining biomarkers from DNA, RNA, and protein. <i>Current Oncology Reports</i> , 2006, 8, 484-491.	1.8	10

#	ARTICLE	IF	CITATIONS
685	Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. <i>Cancer Cell</i> , 2006, 9, 225-238.	7.7	435
686	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. <i>Cancer Cell</i> , 2006, 10, 145-157.	7.7	137
687	Point mutations of protein kinases and individualised cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2243-2261.	0.9	27
688	Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward. <i>Clinical Cancer Research</i> , 2006, 12, 3661-3697.	3.2	263
689	A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15014-15019.	3.3	85
690	Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia. <i>Cancer Research</i> , 2006, 66, 3737-3746.	0.4	101
691	Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 637-644.	1.9	95
692	Assessing BRCA Carrier Probabilities in Extended Families. <i>Journal of Clinical Oncology</i> , 2006, 24, 354-360.	0.8	99
693	Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and Metastasis. <i>Journal of Biological Chemistry</i> , 2006, 281, 22786-22793.	1.6	146
694	Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2512-2521.	1.9	607
695	Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene $\hat{\pm}$ in Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 2740-2748.	0.4	82
696	An Inherent Role of Integrin-Linked Kinase-Estrogen Receptor $\hat{\pm}$ Interaction in Cell Migration. <i>Cancer Research</i> , 2006, 66, 11030-11038.	0.4	41
697	Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6598-6602.	3.2	52
698	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16472-16477.	3.3	292
699	Phosphorylation of TNF- $\hat{\text{A}}$ converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6901-6906.	3.3	130
700	Autophosphorylation of Akt at Threonine 72 and Serine 246. <i>Journal of Biological Chemistry</i> , 2006, 281, 13837-13843.	1.6	25
701	High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins.. <i>Blood</i> , 2006, 108, 107-107.	0.6	5
702	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257008.	1.2	87

#	ARTICLE	IF	CITATIONS
703	Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 988-1004.	21.5	1,853
704	Emerging Role of RAB GTPases in Cancer and Human Disease: Figure 1.. <i>Cancer Research</i> , 2005, 65, 2516-2519.	0.4	198
705	Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1681-1688.	1.9	90
706	ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. <i>Human Molecular Genetics</i> , 2005, 14, 3219-3225.	1.4	60
707	Atypical PKC α contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 12519-12524.	3.3	231
708	Role of Glycogen Synthase Kinase 3 β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity. <i>Cancer Research</i> , 2005, 65, 1961-1972.	0.4	98
709	A Ras Homologue Member 1 Directly Inhibits Signal Transducers and Activators of Transcription 3 Translocation and Activity in Human Breast and Ovarian Cancer Cells. <i>Cancer Research</i> , 2005, 65, 6701-6710.	0.4	42
710	Assay of Rab25 Function in Ovarian and Breast Cancers. <i>Methods in Enzymology</i> , 2005, 403, 202-215.	0.4	38
711	Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1146-1156.	1.9	80
712	Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4968-4976.	3.2	25
713	Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors. <i>Cancer Research</i> , 2005, 65, 3336-3346.	0.4	505
714	Integrative Epidemiology: From Risk Assessment to Outcome Prediction. <i>Journal of Clinical Oncology</i> , 2005, 23, 267-275.	0.8	60
715	Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. <i>Journal of Biological Chemistry</i> , 2005, 280, 2092-2104.	1.6	60
716	Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 346-355.	2.5	278
717	Structure-Activity Relationships of Fluorinated Lysophosphatidic Acid Analogues. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3319-3327.	2.9	78
718	Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon. <i>Clinical Cancer Research</i> , 2005, 11, 6116-6126.	3.2	283
719	Stem cell-ness: a "magic marker" for cancer. <i>Journal of Clinical Investigation</i> , 2005, 115, 1463-1467.	3.9	32
720	Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s).. <i>Blood</i> , 2005, 106, 1219-1219.	0.6	1

#	ARTICLE	IF	CITATIONS
721	Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA).. Blood, 2005, 106, 484-484.	0.6	3
722	Therapeutic potential of phosphoinositide 3-kinase inhibitors. Expert Opinion on Therapeutic Patents, 2004, 14, 703-732.	2.4	34
723	Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells. Journal of Biological Chemistry, 2004, 279, 9653-9661.	1.6	172
724	Glycogen Synthase Kinase β Is a Negative Regulator of Growth Factor-induced Activation of the c-Jun N-terminal Kinase. Journal of Biological Chemistry, 2004, 279, 51075-51081.	1.6	42
725	Lineage Infidelity of MDA-MB-435 Cells. Cancer Research, 2004, 64, 3479-3485.	0.4	152
726	Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 1013-1023.	3.2	269
727	A Genetically Defined Model for Human Ovarian Cancer. Cancer Research, 2004, 64, 1655-1663.	0.4	259
728	The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature Medicine, 2004, 10, 1251-1256.	15.2	463
729	Molecular therapeutics: promise and challenges. Seminars in Oncology, 2004, 31, 39-53.	0.8	24
730	Lysophosphatidic acid production and action: Validated targets in cancer?. Journal of Cellular Biochemistry, 2004, 92, 1115-1140.	1.2	91
731	Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis. Clinical Cancer Research, 2004, 10, 3291-3300.	3.2	399
732	Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 7031-7042.	3.2	303
733	Differential Effects of Three Small Molecules Blocking Phosphatidylinositol-3 Kinase or AKT in Hodgkin Disease Cell Lines: Induction of Apoptosis and Cell Cycle Arrest.. Blood, 2004, 104, 428-428.	0.6	7
734	Mesenchymal Stem Cells Promote Survival of Leukemic Cells Via Integrin-Linked Kinase (ILK)-Dependent Akt and STAT3 Activation: Implications for Leukemia Therapy.. Blood, 2004, 104, 3377-3377.	0.6	0
735	Specific Keynote: Genome Copy Number Abnormalities in Ovarian Cancer. Gynecologic Oncology, 2003, 88, S16-S21.	0.6	37
736	Discussion: Metastasis and Angiogenesis in Epithelial Ovarian Cancer. Gynecologic Oncology, 2003, 88, S37-S42.	0.6	7
737	General Keynote: Molecular Therapeutics and Pharmacogenomics. Gynecologic Oncology, 2003, 88, S84-S87.	0.6	2
738	Specific Keynote: Molecular Therapeutics in Ovarian Cancer. Gynecologic Oncology, 2003, 88, S88-S92.	0.6	23

#	ARTICLE	IF	CITATIONS
739	Activated Src Protein Tyrosine Kinase Is Overexpressed in Late-Stage Human Ovarian Cancers. <i>Gynecologic Oncology</i> , 2003, 88, 73-79.	0.6	172
740	Overexpression of kallikrein 10 in epithelial ovarian carcinomas. <i>Gynecologic Oncology</i> , 2003, 90, 44-50.	0.6	67
741	Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. <i>Oncogene</i> , 2003, 22, 484-497.	2.6	55
742	ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. <i>Oncogene</i> , 2003, 22, 2897-2909.	2.6	100
743	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. <i>Oncogene</i> , 2003, 22, 2812-2822.	2.6	449
744	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. <i>Oncogene</i> , 2003, 22, 3205-3212.	2.6	406
745	The emerging role of lysophosphatidic acid in cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 582-591.	12.8	1,010
746	Enantioselective Responses to a Phosphorothioate Analogue of Lysophosphatidic Acid with LPA3 Receptor-Selective Agonist Activity. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5575-5578.	2.9	58
747	Modulators of lysophosphatidic acid signalling. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 1619-1634.	2.4	19
748	Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades. <i>Journal of Biological Chemistry</i> , 2003, 278, 40057-40066.	1.6	218
749	Identification of a Phosphothionate Analogue of Lysophosphatidic Acid (LPA) as a Selective Agonist of the LPA3 Receptor. <i>Journal of Biological Chemistry</i> , 2003, 278, 11962-11969.	1.6	103
750	Transcriptional Activation of the Proglucagon Gene by Lithium and β -Catenin in Intestinal Endocrine L Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 1380-1387.	1.6	71
751	Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 19245-19256.	1.6	319
752	Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival. <i>Journal of Biological Chemistry</i> , 2003, 278, 23630-23638.	1.6	48
753	Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer. <i>Molecular Endocrinology</i> , 2003, 17, 575-588.	3.7	207
754	The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. <i>Cancer Research</i> , 2003, 63, 1073-82.	0.4	115
755	Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 353-60.	1.9	100
756	Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. <i>Cancer Research</i> , 2003, 63, 5446-53.	0.4	183

#	ARTICLE	IF	CITATIONS
757	Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. <i>Clinical Cancer Research</i> , 2003, 9, 3534-45.	3.2	72
758	Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway. <i>Molecular and Cellular Biology</i> , 2002, 22, 2099-2110.	1.1	164
759	Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO. <i>Journal of the National Cancer Institute</i> , 2002, 94, 844-851.	3.0	140
760	Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. <i>Journal of Cell Biology</i> , 2002, 158, 227-233.	2.3	859
761	Use of proteomic patterns in serum to identify ovarian cancer. <i>Lancet, The</i> , 2002, 359, 572-577.	6.3	3,043
762	Proteomic patterns in serum and identification of ovarian cancer. <i>Lancet, The</i> , 2002, 360, 170-171.	6.3	66
763	Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. <i>International Journal of Cancer</i> , 2002, 97, 557-561.	2.3	81
764	Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF- κ B signaling. <i>Oncogene</i> , 2002, 21, 1945-1954.	2.6	183
765	Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. <i>Oncogene</i> , 2002, 21, 2357-2364.	2.6	54
766	Identification of Tissue- and Cancer-Selective Promoters for the Introduction of Genes into Human Ovarian Cancer Cells. <i>Gynecologic Oncology</i> , 2002, 85, 451-458.	0.6	17
767	Mechanisms underlying chemoprevention of ovarian cancer. <i>Clinical Cancer Research</i> , 2002, 8, 7-10.	3.2	227
768	Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. <i>Cancer Research</i> , 2002, 62, 1087-92.	0.4	279
769	Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 989-97.	1.9	182
770	Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C ζ activity. <i>Oncogene</i> , 2001, 20, 8258-8269.	2.6	42
771	Lysophosphatidic Acid Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2001, 93, 762-767.	3.0	224
772	Defective Cytochrome c-dependent Caspase Activation in Ovarian Cancer Cell Lines due to Diminished or Absent Apoptotic Protease Activating Factor-1 Activity. <i>Journal of Biological Chemistry</i> , 2001, 276, 34244-34251.	1.6	107
773	Tyrosine Phosphorylation of p85 Relieves Its Inhibitory Activity on Phosphatidylinositol 3-Kinase. <i>Journal of Biological Chemistry</i> , 2001, 276, 27455-27461.	1.6	211
774	Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1437-1439.	3.0	63

#	ARTICLE	IF	CITATIONS
775	The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. <i>Seminars in Oncology</i> , 2001, 28, 125-141.	0.8	73
776	Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. <i>Oncogene</i> , 2000, 19, 6277-6285.	2.6	9
777	A Gonadotropin-Releasing Hormone-Responsive Phosphatase Hydrolyses Lysophosphatidic Acid within the Plasma Membrane of Ovarian Cancer Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3370-3375.	1.8	47
778	Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer. <i>Annals of the New York Academy of Sciences</i> , 2000, 905, 188-208.	1.8	212
779	Analysis of the EDG2 Receptor Based on the Structure/Activity Relationship of LPA. <i>Annals of the New York Academy of Sciences</i> , 2000, 905, 279-281.	1.8	6
780	SHP-1 Regulates Lck-induced Phosphatidylinositol 3-Kinase Phosphorylation and Activity. <i>Journal of Biological Chemistry</i> , 1999, 274, 27583-27589.	1.6	138
781	PIK3CA is implicated as an oncogene in ovarian cancer. <i>Nature Genetics</i> , 1999, 21, 99-102.	9.4	1,041
782	Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. <i>Oncogene</i> , 1999, 18, 6635-6640.	2.6	242
783	Growth Suppression of Human Ovarian Cancer Cell Lines by the Introduction of a p16 Gene via a Recombinant Adenovirus. <i>Gynecologic Oncology</i> , 1999, 73, 27-34.	0.6	33
784	Adenovirus-Mediated p53 Growth Inhibition of Ovarian Cancer Cells Is Independent of Endogenous p53 Status. <i>Gynecologic Oncology</i> , 1999, 75, 261-266.	0.6	52
785	Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites. <i>Annals of Surgical Oncology</i> , 1999, 6, 373-378.	0.7	240
786	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. <i>Oncogene</i> , 1999, 18, 7034-7045.	2.6	288
787	Interleukin-2 Reverses the Defect in Activation-Induced Apoptosis in T Cells from AutoimmunoprMice. <i>Cellular Immunology</i> , 1998, 183, 1-12.	1.4	19
788	Expression of p16 induces transcriptional downregulation of the RB gene. <i>Oncogene</i> , 1998, 16, 1-8.	2.6	70
789	Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. <i>Current Biology</i> , 1998, 8, 1195-S1.	1.8	428
790	p202 self-associates through a sequence conserved among the members of the 200-family proteins. <i>FEBS Letters</i> , 1998, 438, 21-24.	1.3	18
791	p202 Prevents Apoptosis in Murine AKR-2B Fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 379-382.	1.0	27
792	Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model. <i>Acta OncolA³gica</i> , 1998, 37, 629-640.	0.8	18

#	ARTICLE	IF	CITATIONS
793	Lysophosphatidylcholine Stimulates Activator Protein 1 and the c-Jun N-terminal Kinase Activity. <i>Journal of Biological Chemistry</i> , 1997, 272, 13683-13689.	1.6	69
794	Human hematopoietic cells express two forms of the cytokine receptor common \hat{I}^3 -chain (\hat{I}^3c). <i>Cell Research</i> , 1997, 7, 195-205.	5.7	1
795	Src Kinase Activity Is Regulated by the SHP-1 Protein-tyrosine Phosphatase. <i>Journal of Biological Chemistry</i> , 1997, 272, 21113-21119.	1.6	148
796	Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. <i>Oncogene</i> , 1997, 15, 2589-2596.	2.6	146
797	Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. <i>International Journal of Cancer</i> , 1997, 71, 31-34.	2.3	141
798	Transfection of Human Ovarian Cancer Cells with the HER-2/neuReceptor Tyrosine Kinase Induces a Selective Increase in PTP-H1, PTP-1B, and PTP- \hat{I}^3 Expression. <i>Gynecologic Oncology</i> , 1996, 61, 233-240.	0.6	18
799	Cell Cycle Progression Out of G1 Sensitizes Primary-Cultured Nontransformed T Cells to TCR-Mediated Apoptosis. <i>Cellular Immunology</i> , 1996, 170, 260-273.	1.4	49
800	Functional LCK Is Required for Optimal CD28-mediated Activation of the TEC Family Tyrosine Kinase EMT/ITK. <i>Journal of Biological Chemistry</i> , 1996, 271, 7079-7083.	1.6	68
801	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. <i>Cancer</i> , 1995, 76, 1615-1620.	2.0	18
802	Effect of lysophospholipids on signaling in the human Jurkat T cell line. <i>Journal of Cellular Physiology</i> , 1995, 163, 441-450.	2.0	82
803	Growth Signal Transduction by the Human Interleukin-2 Receptor Requires Cytoplasmic Tyrosines of the \hat{I}^2 Chain and Non-tyrosine Residues of the \hat{I}^3c Chain. <i>Journal of Biological Chemistry</i> , 1995, 270, 21729-21737.	1.6	65
804	Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. <i>International Immunology</i> , 1995, 7, 1451-1458.	1.8	131
805	Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. <i>Cancer</i> , 1994, 74, 93-99.	2.0	65
806	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-a chain immunotoxin. <i>International Journal of Cancer</i> , 1994, 59, 242-247.	2.3	15
807	Levels of soluble interleukin-2 receptor- \hat{I}^3 are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 170, 918-928.	0.7	23
808	EVIDENCE THAT INCREASES IN LYMPHOCYTE TYROSINE PHOSPHORYLATION PRECEDE CARDIAC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1994, 58, 451-457.	0.5	5
809	Introduction: Transmembrane signaling through hematopoietin receptors: interleukin-2 and erythropoietin. <i>Seminars in Immunology</i> , 1993, 5, 297-298.	2.7	6
810	Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. <i>Seminars in Immunology</i> , 1993, 5, 345-364.	2.7	30

#	ARTICLE	IF	CITATIONS
811	Role of Aberrant Sialylation of Chronic Myeloid Leukemia Granulocytes on Binding and Signal Transduction by Chemotactic Peptides and Colony Stimulating Factors. <i>Leukemia and Lymphoma</i> , 1993, 11, 79-90.	0.6	8
812	The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. <i>Carcinogenesis</i> , 1993, 14, 669-674.	1.3	8
813	Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. <i>International Immunology</i> , 1992, 4, 1233-1243.	1.8	31
814	T-lymphocyte proliferation: tyrosine kinases in interleukin 2 signal transduction. <i>Best Practice and Research: Clinical Haematology</i> , 1992, 5, 551-573.	1.1	15
815	Immunogold Labeling of the Low-Affinity (55 kd) IL2 Receptor on the Surface of IL2 Receptor-Bearing Cultured Cells and Mitogen-Activated Peripheral Blood Lymphocytes. <i>Journal of Leukocyte Biology</i> , 1990, 48, 213-219.	1.5	4
816	Chapter 19 Activation of Lymphocytes by Lymphokines. <i>Current Topics in Membranes and Transport</i> , 1990, 35, 495-535.	0.6	3
817	Expression of ras oncogene leads to down-regulation of protein kinase C. <i>International Journal of Cancer</i> , 1990, 45, 1177-1183.	2.3	29
818	Interrelationship between signals transduced by phytohemagglutinin and interleukin 1. <i>Journal of Cellular Physiology</i> , 1990, 142, 539-551.	2.0	13
819	Role of protein kinase c in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion. <i>Journal of Cellular Physiology</i> , 1989, 141, 310-317.	2.0	13
820	Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor- β mRNA accumulation by the protein kinase C inhibitor staurosporine. <i>FEBS Letters</i> , 1989, 243, 404-408.	1.3	7
821	Increase of serum interleukin 2 receptor level in thermally injured patients. <i>Clinical Immunology and Immunopathology</i> , 1989, 51, 205-215.	2.1	41
822	Uptake of extracellular Ca ²⁺ and not recruitment from internal stores is essential for T lymphocyte proliferation. <i>European Journal of Immunology</i> , 1988, 18, 917-922.	1.6	73
823	Interferon and phorbol esters down-regulate sIgM expression by independent pathways. <i>Journal of Cellular Physiology</i> , 1988, 134, 245-252.	2.0	6
824	Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores. <i>Journal of Cellular Physiology</i> , 1988, 137, 329-336.	2.0	32
825	Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C. <i>Cell</i> , 1988, 55, 91-100.	13.5	141
826	Response of human B cells to different anti-immunoglobulin isotypes: Absence of a correlation between early activation events and cell proliferation. <i>European Journal of Immunology</i> , 1987, 17, 1737-1742.	1.6	15
827	Osmotic activation of the Na ⁺ H ⁺ antiport in protein kinase C-depleted lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , 1986, 134, 8-13.	1.0	59
828	Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. <i>European Journal of Immunology</i> , 1986, 16, 907-912.	1.6	85

#	ARTICLE	IF	CITATIONS
829	Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population. <i>Journal of Clinical Immunology</i> , 1985, 5, 345-356.	2.0	10
830	Mitogens trigger a calcium-independent signal for proliferation in phorbol-ester-treated lymphocytes. <i>Nature</i> , 1985, 315, 419-420.	13.7	87
831	Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. <i>Cellular Immunology</i> , 1985, 95, 146-156.	1.4	16
832	Interleukin 2 in cell-mediated immune responses. <i>Journal of Supramolecular Structure</i> , 1980, 13, 271-280.	2.3	8
833	Cellular Origins and Targets of Costimulator (IL2). <i>Immunological Reviews</i> , 1980, 51, 157-175.	2.8	53
834	Molecular targets for epithelial ovarian cancer. , 0, , 606-618.		0